Physician profile
Mohammad A Eldeeb
NPI 1932213568
$8,648.38
in general payments reported to CMS, 2019-2025
37 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $1,404 · 2021: $2,416 · 2022: $492 · 2023: $589 · 2024: $1,014 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Travel and Lodging: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.83 |
| Travel and Lodging | $878.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,377.59 | 2019-2024 | Senza |
| Boston Scientific Corporation | $1,678.52 | 2019-2025 | General - Therapies, Wavewriter Alpha Prime 16, General - Pain Management |
| Biohaven Pharmaceuticals, INC. | $1,308.21 | 2020-2021 | |
| Abbvie INC. | $500.51 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $338.80 | 2020-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $331.66 | 2019-2024 | Ztlido |
| Pfizer INC. | $285.97 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $236.08 | 2019-2021 | |
| Allergan, INC. | $225.68 | 2019-2022 | |
| Amgen INC. | $136.50 | 2019-2022 | |
| Abbott Laboratories | $124.72 | 2020-2024 | Eterna, Proclaim |
| Novartis Pharmaceuticals Corporation | $123.94 | 2019-2021 | |
| Lilly USA, LLC | $115.56 | 2019-2022 | |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Medtronic, INC. | $80.91 | 2024 | Intellis Adaptivestim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $71.95 | 2022-2024 | |
| Grt US Holding, INC. | $71.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.42 | 2019 | |
| Medtronic USA, INC. | $52.80 | 2019-2020 | |
| Ibsa Pharma INC. | $44.27 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $43.18 | 2019-2020 | |
| Averitas Pharma INC. | $40.45 | 2023-2024 | Qutenza |
| Bioventus LLC | $39.56 | 2024 | Durolane |
| Hikma Pharmaceuticals USA | $34.83 | 2022 | |
| Relievant Medsystems, INC. | $28.32 | 2023 | Intracept |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.96 | 2022 | |
| Stryker Corporation | $20.59 | 2021 | |
| Nalu Medical, INC. | $20.17 | 2021 | |
| Globus Medical, INC. | $18.28 | 2025 | Senza |
| Ge Healthcare | $17.55 | 2025 | |
| Pacira Therapeutics, INC. | $17.05 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.67 | 2024 | Iovera, Zilretta |
| Biodelivery Sciences International, INC. | $13.95 | 2021 | |
| Horizon Therapeutics Plc | $13.81 | 2020 | |
| Stimwave Technologies Incorporated | $13.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Eldeeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.